Status:
COMPLETED
EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Primary Peritoneal Cavity Cancer
Stage I Endometrial Carcinoma
Eligibility:
FEMALE
18+ years
Phase:
PHASE2
Brief Summary
This phase II trial is studying how well EF5 works in finding oxygen in tumor cells of patients who are undergoing surgery or biopsy for cervical, endometrial, or ovarian epithelial cancer. Diagnostic...
Detailed Description
PRIMARY OBJECTIVES: I. Correlate the level of EF5 binding with pre-treatment hemoglobin level and tumor grade and stage in patients undergoing surgery or biopsy for cervical, endometrial, or ovarian ...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Histologically confirmed\* diagnosis of 1 of the following:
- Cervical cancer
- Ovarian epithelial cancer
- Endometrial cancer
- Peritoneal cavity cancer
- Requires surgery or biopsy for diagnosis or as standard initial treatment for the tumor
- Performance status - ECOG 0-2
- WBC ≥ 2,000/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Bilirubin normal
- Creatinine normal
- Creatinine clearance ≥ 60 mL/min
- No significant cardiac condition that would preclude study participation
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 1 month after study participation
- Weight ≤ 130 kg
- No other significant medical condition that would preclude study participation
- No scheduled chemotherapy for the tumor within the past 3 months
- No scheduled radiotherapy to the tumor within the past 3 months
- No other concurrent investigational agents
Exclusion
Key Trial Info
Start Date :
February 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT00107445
Start Date
February 1 2005
Last Update
January 16 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Abramson Cancer Center of The University of Pennsylvania
Philadelphia, Pennsylvania, United States, 19104